Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Indofarma Tbk's Beginning Cash Position for the quarter that ended in Mar. 2026 was Rp5,686 Mil.
PT Indofarma Tbk's quarterly Beginning Cash Position
increased
from Sep. 2025 (Rp5,352 Mil) to Dec. 2025 (Rp34,658 Mil) but then
declined
from Dec. 2025 (Rp34,658 Mil) to Mar. 2026 (Rp5,686 Mil).
PT Indofarma Tbk's annual Beginning Cash Position
declined
from Dec. 2023 (Rp269,751 Mil) to Dec. 2024 (Rp17,071 Mil) and
declined
from Dec. 2024 (Rp17,071 Mil) to Dec. 2025 (Rp9,256 Mil).
PT Indofarma Tbk Beginning Cash Position Related Terms
PT Indofarma Tbk Beginning Cash Position Historical Data
* Premium members only.
The historical data trend for PT Indofarma Tbk's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Beginning Cash Position of Rp5,686 Mil mean?
PT Indofarma Tbk (ISX:INAF) has a Beginning Cash Position of Rp5,686 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PT Indofarma Tbk and its competitors.
Is PT Indofarma Tbk's Beginning Cash Position too high?
PT Indofarma Tbk's current Beginning Cash Position is Rp5,686 Mil. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's Beginning Cash Position compare to ZTS and VTRS?
PT Indofarma Tbk's Beginning Cash Position of Rp5,686 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PT Indofarma Tbk and its competitors. PT Indofarma Tbk's current Beginning Cash Position is Rp5,686 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current Beginning Cash Position of Rp5,686 Mil. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current Beginning Cash Position is Rp5,686 Mil. PT Indofarma Tbk's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current Beginning Cash Position is Rp5,686 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued.
The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.
Key valuation signals for ISX:INAF:
Beginning Cash Position: Rp5,686 Mil
GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score
Get the complete analysis for ISX:INAF
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:INAF has been successfully added to your 
